Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?
Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?
复制标题
DOI：
10.3390/cancers13112708
复制
发表时间：
2021-05-30
期刊：
影响因子：
5.2
通讯作者：
Neuzillet C
中科院分区：
文献类型：
--
作者：
Boilève A;Hilmi M;Delaye M;Tijeras-Raballand A;Neuzillet C
在肿瘤学中，随着靶向和免疫疗法的发展，在过去十年中出现了一个新的时代。在肝细胞癌（HCC）中，几种靶向药物（sorafenib, lenvatinib, cabozantinib， regorafenib和ramucirumab）被批准，免疫疗法现在与贝伐单抗联合验证，而缺乏用于患者选择的治疗诊断生物标志物。相反，在胆道癌（BTC）中，免疫疗法仍处于研究阶段，而考虑到BTC复杂的分子结构，靶向治疗现在至关重要。在这篇综述中，我们概述了(i) HCC和BTC的主要预后生物标志物，（ii）这两种肿瘤的主要诊断生物标志物，以及（iii）临床实践中推荐的生物标志物。肝细胞癌（HCC）和胆道癌（BTC）表现出较差的预后，所有分期的5年总生存率约为15%。大多数原发性肝脏恶性肿瘤在诊断时已转移，只有有限的治疗选择，主要依靠全身治疗。HCC和BTC的治疗方式不同，但有部分重叠。BTC复杂的分子特征产生了几个可行的治疗靶点，这与HCC相反，HCC仍然是非分子选择患者的抗血管生成药物领域。目前，免疫疗法联合贝伐单抗在HCC的一线治疗中得到了验证，而单药免疫疗法的临床活性似乎仅限于一小部分BTC患者，这些患者的特征仍然很差，目前正在研究联合治疗。在这篇综述中，我们对以下方面的临床相关性进行了关键评估和分级：(1)HCC和BTC的主要预后生物标志物，(2)这两种肿瘤的主要诊断生物标志物，以及(3)临床实践中推荐的生物标志物。
In oncology, a new era has emerged in the last ten years with the development of targeted and immune therapies. In hepatocellular carcinoma (HCC), several targeted agents (sorafenib, lenvatinib, cabozantinib, regorafenib, and ramucirumab) are approved and immunotherapy is now validated in combination with bevacizumab, while theragnostic biomarkers are lacking for patient selection. Conversely, in biliary tract cancer (BTC), immune therapies are still investigational while targeted therapies are now crucial considering the complex molecular landscape of BTC. In this review, we provide an overview of (i) the main prognostic biomarkers in HCC and BTC, (ii) the main theragnostic biomarkers in both tumors, and lastly (iii) what is recommended in clinical practice. Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) exhibit a poor prognosis with 5-year overall survival rates around 15%, all stages combined. Most of these primary liver malignancies are metastatic at diagnostic, with only limited therapeutic options, relying mainly on systemic therapies. Treatment modalities are different yet partially overlapping between HCC and BTC. The complex molecular profile of BTC yields to several actionable therapeutic targets, contrary to HCC that remains the field of antiangiogenic drugs in non-molecularly selected patients. Immunotherapy is now validated in the first line in HCC in combination with bevacizumab, while clinical activity of single agent immunotherapy appears limited to a subset of patients in BTC, still poorly characterized, and combinations are currently under investigation. In this review, we provide a critical evaluation and grading of clinical relevance on (i) the main prognostic biomarkers in HCC and BTC, (ii) the main theragnostic biomarkers in both tumors, and lastly (iii) what is recommended in clinical practice.
登录
查看更多内容
影响因子：
2.4
作者：
Ahn KS;Kang KJ
通讯作者：
Kang KJ
影响因子：
64.5
作者：
Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu;Cancer Genome Atlas Research Network
通讯作者：
Cancer Genome Atlas Research Network
DOI：
10.1016/s1470-2045(20)30157-1
发表时间：
2020-06
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Abou-Alfa GK;Macarulla T;Javle MM;Kelley RK;Lubner SJ;Adeva J;Cleary JM;Catenacci DV;Borad MJ;Bridgewater J;Harris WP;Murphy AG;Oh DY;Whisenant J;Lowery MA;Goyal L;Shroff RT;El-Khoueiry AB;Fan B;Wu B;Chamberlain CX;Jiang L;Gliser C;Pandya SS;Valle JW;Zhu AX
通讯作者：
Zhu AX
影响因子：
65.1
作者：
Banales, Jesus M.;Cardinale, Vincenzo;Alvaro, Domenico
通讯作者：
Alvaro, Domenico
影响因子：
13.5
作者：
Calderaro, Julien;Rousseau, Benoit;Pawlotsky, Jean-Michel
通讯作者：
Pawlotsky, Jean-Michel